Skip to main content

Regulus Licenses miRNA-Modulation Inventions from CalTech

Premium

Regulus Therapeutics, the microRNA drug joint venture of Alnylam Pharmaceuticals and Isis Pharmaceuticals, said this week that it has exclusively licensed California Institute of Technology inventions related to the modulation of miR-146 and miR-155, key mediators of the inflammatory response.

According to the company, miR-155 has been found to be induced during the macrophage inflammatory response and is a common target of a broad range of inflammatory mediators. "As miR-155 is known to function as an oncogene, these observations suggest a link between inflammation and cancer," Regulus noted.

Meanwhile, miR-146 "is induced, in an NF-kB-dependent manner, in response to proinflammatory mediators," the company added. "These findings suggest that modulation of miR-146 may be of therapeutic benefit in treating diseases characterized by excessive activation of innate immunity signaling."

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.